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Resveratrol more effectively than quercetin reduces endothelium degeneration  
and level of necrosis factor α in patients with coronary artery disease
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HigHer State educational eStabliSHment of ukraine 
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ABSTRACT
Introduction: endothelial dysfunction (ed) is one of the most important links in the pathogenesis of atherosclerosis (aSVd) — morphological basis of 
coronary artery disease (cad).
Objective: to study the effect of polyphenolic antioxidants, resveratrol and quercetin, on endothelial degeneration factors in cad patients.
Materials and Methods: the study involved 93 patients with coronary artery disease: stable angina pectoris, fc ii. the cytofluorometric technique was applied 
to define the level of circulating endothelial microparticles (emP) cd32+cd40+ in peripheral blood in order to identify ed. the content of tumor necrosis factor 
α (tnf-α), fibrinogen, hemocoagulation and lipid profile parameters were being determined in the blood, as well. Patients were divided into 3 groups. basic 
therapy (β-blockers, statins, aspirin) was prescribed to 33 persons of the comparison group, patients of the study group 1 (30 persons) additionally received 
resveratrol at a dose of 100 mg daily, patients of the study group 2 (30 persons) got quercetin at a dose of 3 g per day. in 2 months, the second examination of 
the patients was performed in the amount indicated.
Results: under the influence of resveratrol a significant reduction of the level of tnf-α and the number of emP in peripheral blood was shown, in contrast to 
the results of other study groups. all groups showed a decrease in total cholesterol and low-density lipoprotein cholesterol, statistical differences between 
data of groups were not found. indicators of coagulogramma in all study groups did not change significantly, however, there was a statistically significant 
reduction of fibrinogen in the blood.
Conclusions: resveratrol, unlike quercetin, has a positive effect on the endothelial function and systemic inflammation, which may be the result of its influence 
on intracellular molecular cascades associated with the nuclear transcription factor of nf-kb.
Key words: coronary artery disease, endothelial dysfunction, resveratrol, quercetin, circulating endothelial microparticles.
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INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of mortality 
in Ukraine (67.3%), with dominating coronary heart disease 
(68.8%). Coronary artery disease (CAD) tops the list of 10 
leading causes of death globally (12.8%) [1]. Morphological 
basis of CAD is atherosclerosis (ASVD), in particular, of the 
coronary arteries. Endothelial dysfunction (ED) is one of the 
most important links in the pathogenesis of atherosclerosis 
(ASVD) [2].
Violation of vasomotor, hemostatic, adhesive, angiogenic 
properties of the endothelium (ET) is the result of direct 
or indirect damage to cell membranes by free radicals, the 
oxidation-modified low-density lipoproteins (LDL), antigenic 
complexes, monocytes, macrophages, cytokines (CK), which 
leads to activation of endotheliocytes with possible subsequent 
apoptosis [3]. Prolonged exposure to activating factors contributes 
to the formation of a persistent imbalance of all endothelium-
dependent functions. Chronic inflammation of low intensity, 
which is the pathogenetic basis of ASVD, supports ED. Thus 
ET, in turn, having a potent paracrine function, mediates and 
implements proinflammatory reaction, making a vicious cycle 
of vascular lesions` formation [4]. Proceeding from the above, 
the search for effective correctors of ED, both of preventive 
and therapeutic action, is a perspective direction of modern 
medicine [5].
Our attention has been attracted by stilbene phytoalexin, 
resveratrol. Resveratrol is a polyphenol representative, it contains 
2 aromatic rings and 3 reactive hydroxyl groups that contribute 
to its antioxidant activity. Resveratrol is found in more than 
30 species of plants, providing protection from the damaging 
action of bacteria, viruses, ultraviolet exposure [6]. Molecular 
targets of resveratrol are nuclear factor kappa-B (NF-kB), 
sirtuin-1 (SIRT-1), NO, sNOS/eNOS, adenosine receptors, 
free radicals, adhesion molecules ICAM, VCAM, E-selectin, 
MAP-kinase and many others [7, 8, 9]. It is flavonoid quercetin 
that has similar chemical structure and is well studied and 
having demonstrated the protective properties in acute coronary 
syndrome [10, 11].
AIM
The aim of our study was to investigate the effect of resveratrol 
compared with quercetin on the ED indicators, systemic 
inflammation, lipid blood profile and hemocoagulation in 
patients with stable coronary artery disease.
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MATERIAL AND METHODS
The research involved 113 people. The study group included 
93 patients (26 females and 18 males), aged 48 to 72, with the 
diagnosis of CAD: stable angina pectoris, FC II, CH 0-I, the average 
risk. Exclusion criteria were Stage 2 hypertension, rheumatic 
diseases, diabetes mellitus, chronic liver disease and kidney 
failure. The control group consisted of 20 healthy individuals. 
Every patient gave a written informed consent to participate in 
the research, according to the requirements of the Declaration 
of Helsinki. CAD diagnosis was confirmed clinically, by the data 
of cardiac stress testing and echocardiography (echo). Treadmill 
ergometer was used with a continuously increasing step-by-step 
protocol of dosed physical load with duration of one stage of 
2 minutes. The test was considered to be “positive” in the case 
of occurrence of objective evidence of myocardial ischemia 
during the trial, functional class (FC) of CAD was determined by 
performing the declared load capacity, every patient completed a 
load capacity of 75 W, which corresponded to FC II. Using echo, 
central hemodynamics was being studied to identify systolic 
and diastolic dysfunction of the left ventricle (LV). Patients of 
the study groups had a saved ejection fraction (EF) of LV or 
its slight decrease (45-50%). All the patients showed signs of 
diastolic dysfunction by the type of violation of relaxation (type 
1). In the presence of clinical symptoms (shortness of breath 
with exertion, palpitations, fatigue) and decrease in LVEF in 
the specified range, the diagnosis of heart failure (HF) with 
preserved systolic function (52% of patients with CAD) was 
established. The degree of risk was determined by the total 
assessment using SCORE table that was less than 2.3% of 10-year 
risk of mortality, and the values of LVEF, which corresponded 
to less than 3% of annual mortality risk. Therefore, the average 
risk for every patient of the study groups was established [12]. 
Standard therapy for coronary artery disease patients, together 
with recommendations for lifestyle (diet therapy, dosed physical 
exertion, smoking cessation), was prescribed; medications were 
also used: beta-blockers (5 mg of bisoprolol once a day in the 
morning), statins (10 mg of atorvastatin once a day at bedtime), 
75 mg of aspirin at bedtime. After stabilization of the clinical 
course of CAD in a month after the start of the base treatment, 
resveratrol at a dose of 100 mg per day in one portion per os 
was additionally administered to patients of the study group 
1, patients of the study group 2 were prescribed quercetin at a 
dose of 3 g per day per os. Before therapy with resveratrol and 
quercetin and after 2 months of starting treatment, clinical 
laboratory tests were conducted to patients.
For objectification of patients` condition before and after 
treatment an EQ-5D quality of life questionnaire with the 
expectation of EQ-5D index and parallel identification of the data 
on a visual analog scale EQ-5D-VAS was used. As a marker of ET 
damage, circulating in the bloodstream endothelial microparticles, 
formed as a result of apoptosis or activation of endothelial 
proinflammatory agents, were being studied. Determination 
of circulating endothelial microparticles (EMP) was made by 
identifying the expression of endothelial cell antigens CD32 and 
CD40 with monoclonal antibodies by flow cytofluorometry [13]. 
To assess the severity of chronic systemic inflammation, the 
concentration of tumor necrosis factor (TNF-α) in blood serum was 
determined by immunoassay and the concentration of fibrinogen 
in the blood — by gravimetric methods. Hemocoagulation 
indicators were being studied as well: prothrombin time index 
(PTI), activated partial thromboplastin time (aPTT), international 
normalized ratio (INR). The content of total cholesterol, LDL 
cholesterol and high-density lipoprotein (HDL) were evaluated 
by photometric method.
Statistical analysis of the results of the research was carried 
out using BioStat and KyPlot programs. The hypothesis of normal 
distribution was checked by Shapiro – Wilk test. When comparing 
these study groups before and after treatment, paired Student’s 
t-test was used, for inappropriate distribution — Wilcoxon 
signed-rank test and Fisher’s exact test. When comparing data 
between groups, unpaired Student’s t-test and Steel – Dwass test 
(nonparametric analogue of Tukey’s range test) or Wicocson 
test were used. Search for relations between variables was held 
using Pearson`s correlation or, subject to maldistribution, using 
Spearman`s and Kendall`s rank correlation. Data differences 
were considered to be significant at a level of p < 0.05.
RESULTS
The mean EQ-5D-index score before treatment in patients 
with coronary artery disease was 0.741 + 0.066, EQ-5D-VAS – 
53.63 + 5.14. Patients taking resveratrol, most often, compared 
with those of other groups, noted the boost of energy, increased 
working capacity, reducing the number and duration of episodes 
of pain in the heart. After a two-month period of treatment, 
results of life quality assessment in this group were significantly 
different from those before treatment: EQ-5D-index was 0.851 
+ 0.059 (p < 0.001), EQ-5D-VAS — 65.47 + 5.19 (p < 0.001). 
Patients treated with quercetin also had a positive dynamics 
of subjective condition: EQ-5D-index was 0.839 + 0.037 (p < 
0.01), EQ-5D-VAS – 62.92 + 5.82 (p < 0.001). In the comparison 
group after treatment EQ-5D-index also increased 0.809 + 0.057 
(< 0.001), EQ-5D-VAS rather significantly changed — 58,81 + 
6.09 (p < 0.01).
After the treatment in each study group total cholesterol 
level and LDL cholesterol decreased, HDL cholesterol level did 
not change significantly (Table I). No significant differences 
between the results of the groups were revealed.
Analysis of hemocoagulation indicators showed that 
34% of patients with stable coronary artery disease at initial 
examination had increased fibrinogen concentration in 
the blood (norm – 2-4 g/L). Before treatment significant 
differences of that indicator in the groups were not revealed 
(Table ІI). The treatment resulted into a significant decrease 
in fibrinogen concentration, more pronounced in patients 
treated with resveratrol (p = 0.0001) and quercetin (p = 
0.0004) than in the control group (p = 0.002). Other indicators 
of hemocoagulation (PTI, aPTT, INR) did not exceed the 
physiological norms before treatment, after the treatment 
they did not significantly change.
In patients with stable coronary artery disease, an increased 
amount of EMP СD32+CD40+ in the blood was found, which 
confirms the presence of ED (Table II). The number of EMP 
СD32+CD40+ in healthy individuals is 1.30 x 107/ L with a range 
of values in Q1-Q3 quartiles (1.05 – 2.11) x 107/ L. Under the 
conventional therapy the number of EMP СD32+CD40+ did not 
change (p = 0.548), as well as in the group of patients treated with 
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additional quercetin (p = 0.312). A statistically significant decrease of 
EMP СD32+CD40+ proved to be under resveratrol (p = 0.038).
Also, every patient before treatment revealed increased TNF-α 
in the blood (normal value – 0.5 (0-6) pg/mL). A statistically 
significant decrease in TNF-α under resveratrol (p = 0.013) and 
a tendency to its decrease in patients treated with quercetin (p 
= 0.06) (Table II) was found out.
Between the number of EMP and other indices studied 
correlations have not been identified, which may indicate a narrow 
specificity of EMP as an independent marker of ED. In addition 
to sound close direct correlation between cholesterol, triglycerides 
and LDL cholesterol, moderate correlations between fibrinogen 
and TNF-a, cholesterol, LDL cholesterol and triglyceride levels 
have been found out (Table III).
Group /
Mark
St
at
ist
ica
l
in
de
x
Cholesterol,
mmol/l LDL cholesterol, mmol/l HDL cholesterol, mmol/l
Triglycerides, 
mmol/l
Before
treatment
After 
treatment
Before
treatment
After
 treatment
Before
treatment
After 
treatment
Before
treatment
After 
treatment
group 
of comparison
Х
σ
sx
5,48 +
1,05
0,262
4,74 +
0,61
0,153
3,43 +
0,76
0,189
2,74 +
0,52
0,129
1,12 + 0,24
0,061
1,16 + 0,17
0,042
2,11 +
0,54
0,135
1,91 +
0,35
0,086
р < 0,01 < 0,001 > 0,05 < 0,05
group 
of investigation1
(resveratrol)
Х
σ
sx
5,38 +
0,90
0,221
4,48 +
0,75
0,176
3,45 +
0,79
0,183
2,46 +
0,60
0,141
1,03 + 0,22
0,052
1,07 + 0,20
0,047
2,04 +
0,37
0,087
1,88 +
0,35
0,083
р < 0,001 < 0,001 > 0,05 < 0,001
group 
of investigation 2
 (quercetin)
Х
σ
sx
5,14 +
0,96
0,257
4,35 +
0,84
0,223
3,16 +
0,71
0,19
2,42 +
0,65
0,173
1,12 + 0,22
0,058
1,15 + 0,18
0,047
1,89 +
0,43
0,114
1,71 +
0,34
0,091
р < 0,001 < 0,001 > 0,05 < 0,01
Table I. indicators of lipid blood profile in patients of the study groups.
note: X – the sample mean, σ – standard deviation, sx – the standard error of the mean.
Group/
Mark
St
at
ist
ica
l
in
de
x
TnFα,
pg/мml
Fibrinogen, 
g/l
EMP  CD32+CD40+,
х 107/l
St
at
ist
ica
l
in
de
x
Before
treatment
After 
treatment
Before
treatment
After treat-
ment
Before
treatment
After 
treatment
group 
of comparison
Х
σ
р
8,53
+3,24
8,34
+2,17
3,78
+0,91
3,17
+0,35
1,73
+0,23
(0,97-4,00)
1,85
+0,19
(0,94-3,56)
Ме
sМе
Q1-Q3
р=0,866 р=0,002 р=0,547*
group 
of investigation1
(resveratrol)
Х
σ
р
9,69
+1,86
7,28
+2,33
4,06
+0,85
2,92
+0,41
1,93
+0,20
(1,25-4,55)
1,40
+0,13
(1,09-2,59)
Ме
sМе
Q1-Q3
р=0,013 р=0,0001 р=0,038*
group 
of investigation 2
 (quercetin)
Х
σ
7,80
+2,44
5,98
+1,81
3,53
+0,63
2,71
+0,77
1,8
+0,26
(0,98-4,93)
2,11
+0,13
(1,15-3,93)
Ме
sМе
Q1-Q3
р =0,060 р=0,0004 р=0,221*
Table II. the indicators of systemic inflammation and endothelial destruction in patients of the study groups.                             
note: X – the sample mean, σ –  standard quadratic deviation, me - median, sme –  the standard error of the median, Q1 - Q3 –  upper and lower quartiles; * – Wilcocson (u).
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DISCUSSION
The revealed correlations between the indices of lipid spectrum 
of the blood and mediators of chronic SI confirmed their close 
pathogenetic cooperation in the conditions of atherogenesis [2, 
15]. This study has shown normalization of blood lipid parameters 
in each group with no significant predominance. In respect that 
patients of each study group received statins as basic therapy, 
probably lipid-lowering effect of resveratrol and quercetin did 
not exceed that of statins.
While stable coronary artery disease in our research, no 
significant changes in blood coagulation potential have revealed, 
except for the content of fibrinogen, which increase should be 
considered, to a greater extent, as systemic inflammation factor. 
Probably, coagulation changes, characteristic for CAD, such as 
activation factor XII, increased synthesis of thromboxane A2 
with an excess of arachidonic acid when chronic SI, reducing 
the formation of tissue plasminogen activator and antithrombin 
III ET, heparin depletion as a co-enzyme of lipoprotein lipase 
with hyperlipidemia, to a greater extent, are implemented into 
destabilization of the clinical course and the development of 
atherothrombosis.
As a reactant of acute phase of inflammation, fibrinogen 
increases the expression of NF-kB in mononuclear phagocytes by 
CD11b/CD18 receptors, which contributes to the inflammatory 
activation, expression of monocyte chemoattractant protein 
– 1 (MCP-1) and the synthesis of CK (interleukin-1β (IL-1β, 
TNF-α) [16]. Fibrinogen has synergistic effect with IL-1β in the 
activation of fibroblast growth factor-2 (FGF2), which leads to 
an increase of NF-kB signaling in ET [17].
In this research, both studied polyphenols have had significant 
impact on markers of systemic inflammation (fibrinogen and 
TNF-α), with a predominance of the effectiveness of resveratrol. 
Statins have had a corrective effect on fibrinogen content in 
the blood only, but to a lesser extent than in combination with 
polyphenols studied. Probably, for the implementation of the 
pleiotropic anti-inflammatory effect of statins it is necessary 
to use higher doses, according to the current guidelines, or a 
longer period of exposure to the drug is needed. We chose an 
empirical approach to choose doses of statins not to disguise 
the effects of polyphenols studied, but to explore the possible 
benefits of the combination of these drugs.
ED is the earliest stage of atherogenesis, at the same time it 
plays a leading role in the progression of vascular changes, in 
the formation of atheromatous plaques, their destabilization [4]. 
According to the scientific data, statins increase the activity of 
endothelial NO-synthase (eNOS), reduce the formation of CK, 
providing endothelioprotection. Quercetin is also due to membrane-
protective properties helps to protect the ET [18]. In this study 
neither quercetin nor statins have had no significant effect on the 
level of degradation of ET — EMP. Perhaps, the reason for it is 
the low dose of statins, short follow-up and established in various 
studies low bioavailability of quercetin, which necessitates its use 
in coronary artery disease as a parenteral solution. However, over 
the same period a significant corrective effect of resveratrol on 
the pool of EMP in the bloodstream has been found out, which 
is a proof of its pronounced endothelioprotective effect.
In addition to the ability of resveratrol to activate eNOS, its 
inhibitory effect on the nuclear transcription factor kappa B (NF-
кВ), which is a key element of the activation of the inflammatory 
cascade, insulin resistance and the implementation of mechanisms of 
aging, is being discussed [19, 20]. Resveratrol has a blocking effect on 
kappa B inhibitor kinase (ІkB), which prevents the translocation of 
NF-кВ into nucleus and activation of the respective genes encoding 
cytokines, proliferation signaling molecules, chemoattractants, 
adhesion molecules [19, 20]. The action of resveratrol by sirtuin-
activating proteins, in particular sirtuin-1, providing nucleotide 
skeleton density and prevening inclusions of pathogenic genes, has 
also been proved [9, 21]. Apparently, it is the mechanism which is the 
basis of the detected endothelioprotective effect of resveratrol.
There are some studies to demonstrate the inhibitory effect 
of quercetin on NF-кВ-dependent gene expression by reducing 
the TNF-α production [22]. Under the conditions of this study 
only a tendency to decrease TNF-α under quercetin has been 
observed, that probably has not been sufficient to achieve its 
effects relatively to NF-KB (Table II).
Based on the results of this research, it should be assumed that 
resveratrol and quercetin potentiate the direct and pleiotropic 
effects of statins.
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note: * – (р < 0.05), ** – (р < 0.01), ** – (р < 0.001).
emP
cd32+ cd40+                         - - - - -
Тriglyce-rides - 0,412** 0,736*** 0,401**
ldl-cholesterol 0,358** 0,401** 0,944***
chole-sterol 0,270* 0,355**
fibrinogen 0,352**
tnfα
tnfα fibrino-gen chole-sterol ldl-chole-sterol Тriglyce-rides
emP
cd32+
cd40+                         
Table III. the correlation coefficients between the indicators of lipid blood profile, endothelial dysfunction and inflammatory mediators in patients with stable 
coronary artery disease.
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CONCLUSION
Thus, due to a wide range of its biological activity, resveratrol, 
within 2 months of treatment, to a greater extent than quercetin, 
has a positive effect on the function of ET and severity of systemic 
inflammation.
Resveratrol may provide anti-ischemic effect on coronary artery 
disease due to the regulation of intracellular cascades, controling 
cell metabolism, antioxidant effects, endothelioprotection, 
slowing the formation of atherosclerotic lesions that allows 
to recommend it for widespread use in clinical practice as a 
promising angioprotector.
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